Therapeutic antibodies continue to be clinical success stories, especially in the area of immuno-oncology. Recent times have also seen dramatic progress being made in the area of adoptive T-cell therapies. Therefore, providing efficiency gains in the antibody discovery and cell therapy development processes has become a focus of effort at IntelliCyt, a Sartorius Company. Several new application kits have been developed that combine process steps through multiplexing and run on our platform, providing productivity gains in both sampling throughput and analysis/visualization workflows. Several customer case studies will be discussed.
1. Incorporation of the iQue Screener PLUS platform into a novel protein production and drug discovery platform.
Speaker: Ashok Bandaranayake, Director of Bioprocess Development and Automation, Fred Hutch Cancer Center
Fred Hutch Cancer Center has developed an automated drug discovery platform to generate proteins and peptides and then assay them as candidates for immunotherapy. The iQue Screener PLUS is an essential addition to this platform and is used to monitor transduction, cell health and viability during protein production as well as to isotype/titer antibody production and perform T cell killing assays.
2. Screening of AML Neoantigen Specific T cells with the iQue Screener PLUS
Speaker: Alison Tarke, Research Scientist, PersImmune
This talk will describe the identification of AML neoantigen specific T cells using the iQue Screener PLUS to assess CTL activity by target cell death and cytokine release. Additionally, to define leukocyte populations by expression level of CD45 and measure T cell proliferation in response to neoantigens.
Ashok Bandaranayake, Director of Bioprocess Development and Automation, Fred Hutch Cancer Center
Alison Tarke, Research Scientist, PersImmune
Joseph Zock, Senior Director Product Management, IntelliCyt A Sartorius Company
Senior Director, Product Management
IntelliCyt, A Sartorius Company
Alison Tarke graduated from UC Davis with a Bachelor of Science in Neurobiology, Physiology, and Behavior. For the past 5 years she has worked as a research scientist at PersImmune, a private company dedicated to developing a personalized adoptive T cell immunotherapy for cancer patients. Alison is familiar with laboratory techniques necessary for GMP manufacturing and characterization of human immune cells to be used in T cell immunotherapy.
Dir. Bioprocess Development
Optide Program, Fred Hutch Cancer Center
Dr. Bandaranayake earned his undergraduate degree in biochemistry (UC Davis) and his PhD in immunology (University of Washington, Seattle) in order to achieve his goal of developing therapeutics. He was introduced to automation at Albert Einstein College of Medicine where he was a Faculty member working for the New York Structure Consortium and immediately saw the power of harnessing automation in the drug discovery and development process. He then moved to the Fred Hutch to design and develop his own automated pipeline for protein production, antibody development and immuno-oncology assays.
Monday, February 5
12:30 PM – 1:45 PM
The asset you are trying to access is locked. Please enter your access key to unlock.